Table 1.
Site A | Site B | Both Groups | ||||
---|---|---|---|---|---|---|
Pre (N=25) | Post (N=56) | Pre (N=22) | Post (N=34) | Pre (N=47) | Post (N=90) | |
Summary quality score | 44 | 46 | 33 | 46* | 38 | 46* |
Individual Quality Indicators | ||||||
-New memory impairment | ||||||
Assessing cognition | 63 | 67 | 80 | 31 | 69 | 53 |
Reviewing medications | 63 | 71 | 80 | 56 | 69 | 65 |
-New dementia | ||||||
Conducting neurologic exam | 67 | 71 | 60 | 33 | 63 | 54 |
Screening for depression | 67 | 100 | 40 | 83 | 50 | 92 |
Performing laboratory tests | 0 | 0 | 0 | 33 | 0 | 15 |
-Management of dementia | ||||||
Assessing functional status | 30 | 51 | 10 | 50* | 20 | 51* |
Discussing cholinesterase inhibitor | 86 | 67 | 50 | 71 | 75 | 68 |
Screening for behavioral symptoms | 30 | 51 | 76 | 69 | 54 | 58 |
Managing behavioral symptoms | 0 | 4 | 6 | 22 | 5 | 12 |
Discussing risk/benefits of antipsychotics | 50 | 100 | 23 | 100* | 32 | 100* |
Counseling about driving | 33 | 16 | 0 | 27 | 13 | 20 |
Counseling caregiver | 5 | 22 | 0 | 42* | 2 | 30* |
Specifying surrogate | 75 | 62 | 52 | 27 | 63 | 49 |
% referred to Alzheimer's Association | 0 | 9 | 0 | 29* | 0 | 17* |
N= number of patients;
p < 0.05 comparing pre to post